Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds

Executive Summary

User fees won't support dedicated staff, but rather FTEs that will work on the popular program as needed.


Related Content

Breakthrough Denial Doesn't Mean US FDA Won't Bring Full Resources To Application
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
FDA's Breakthrough Bar May Be Set Too Low, Jenkins Says
Breakthrough In Two Pages: FDA Offers Preliminary Advice
‘Breakthrough Therapy’ Designations
PDUFA Negotiations: Early Communications, Breakthrough Still On Docket
Breakthrough Requests: US FDA Adds Quick Screen To Pare Workload
Following Through On Breakthrough: What’s Next For FDASIA Success?
FDA’s Generic Drug Staff To Be Reduced When Workload Under Control
Show Me The Money: Salaries, Red Tape Challenge FDA Recruiting





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts